Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Calypte's oral HIV test:

This article was originally published in Clinica

Executive Summary

The Chinese state Food and Drug Administration (SFDA) has approved Calypte Biomedical's Aware HIV-1/2-OMT rapid oral HIV test. It is the first and only rapid oral fluid HIV diagnostic in the country, the Portland, Oregon-based company claimed. The product will be manufactured and sold by the firm's Chinese subsidiary, Beijing Marr Bio-Pharmaceutical. Calypte said it was "thrilled" with the long-awaited approval - it had originally hoped for a response from the Chinese FDA in mid-2005. HIV incidence in China is rising rapidly, and is expected to reach 15 million by 2010, the firm said. Aware was also approved in India in July 2007 (see Clinica No 1265, p 16).

You may also be interested in...

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts